Anti-SETBP1 / SET binding protein 1

Adding 0.2 ml of distilled water will yield a concentration of 500 ug/ml. SETBP1 antibody detects SET binding protein 1, a nuclear protein that interacts with the SET oncoprotein to regulate chromatin structure, gene expression, and cellular proliferation. SETBP1 modulates transcriptional programs controlling stem cell maintenance and oncogenic transformation. The SETBP1 antibody is used in studies of leukemia, developmental syndromes, and transcriptional regulation.SETBP1 is encoded by the SETBP1 gene on human chromosome 18q12.3. The protein is approximately 170 kilodaltons and contains multiple AT-hook motifs for DNA binding, nuclear localization signals, and a SET-binding domain that mediates interaction with the SET protein, a known inhibitor of protein phosphatase 2A (PP2A). Through this interaction, SETBP1 indirectly modulates PP2A activity, influencing cell cycle progression and epigenetic control.The SETBP1 antibody detects a 145-150 kilodalton band by western blot and shows nuclear localization under immunofluorescence. SETBP1 acts as a transcriptional regulator that binds GC-rich promoter regions to enhance expression of target genes, including HOXA cluster members associated with hematopoietic differentiation and leukemogenesis. Mutations that stabilize SETBP1 lead to aberrant accumulation, transcriptional reprogramming, and malignant transformation in myelodysplastic syndromes and acute myeloid leukemia.In addition to cancer, germline mutations in SETBP1 cause Schinzel-Giedion syndrome, a severe developmental disorder characterized by craniofacial abnormalities and neurological impairment. These mutations increase SETBP1 stability, disrupt normal transcriptional repression, and impair neuronal differentiation. SETBP1 also interacts with chromatin-modifying complexes to coordinate histone acetylation and methylation status.As a molecular bridge between SET and chromatin, SETBP1 integrates signaling pathways that regulate proliferation, apoptosis, and gene expression. NSJ Bioreagents provides a validated SETBP1 antibody optimized for western blot, immunocytochemistry, and chromatin studies, facilitating research into oncogenic transcriptional regulation and epigenetic mechanisms in disease.